↓ Skip to main content

Drug therapy in patients with Parkinson’s disease

Overview of attention for article published in Translational Neurodegeneration, May 2012
Altmetric Badge

Mentioned by

1 tweeter


66 Dimensions

Readers on

133 Mendeley
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Drug therapy in patients with Parkinson’s disease
Published in
Translational Neurodegeneration, May 2012
DOI 10.1186/2047-9158-1-10
Pubmed ID

Thomas Müller


Parkinson`s disease (PD) is a progressive, disabling neurodegenerative disorder with onset of motor and non-motor features. Both reduce quality of life of PD patients and cause caregiver burden. This review aims to provide a survey of possible therapeutic options for treatment of motor and non motor symptoms of PD and to discuss their relation to each other. MAO-B-Inhibitors, NMDA antagonists, dopamine agonists and levodopa with its various application modes mainly improve the dopamine associated motor symptoms in PD. This armentarium of PD drugs only partially influences the onset and occurrence of non motor symptoms. These PD features predominantly result from non dopaminergic neurodegeneration. Autonomic features, such as seborrhea, hyperhidrosis, orthostatic syndrome, salivation, bladder dysfunction, gastrointestinal disturbances, and neuropsychiatric symptoms, such as depression, sleep disorders, psychosis, cognitive dysfunction with impaired execution and impulse control may appear. Drug therapy of these non motor symptoms complicates long-term PD drug therapy due to possible occurrence of drug interactions, - side effects, and altered pharmacokinetic behaviour of applied compounds. Dopamine substituting compounds themselves may contribute to onset of these non motor symptoms. This complicates the differentiation from the disease process itself and influences therapeutic options, which are often limited because of additional morbidity with necessary concomitant drug therapy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 2 2%
United States 2 2%
Canada 1 <1%
Australia 1 <1%
Spain 1 <1%
Luxembourg 1 <1%
Unknown 125 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 24 18%
Student > Bachelor 22 17%
Student > Ph. D. Student 21 16%
Researcher 15 11%
Student > Doctoral Student 11 8%
Other 17 13%
Unknown 23 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 24 18%
Medicine and Dentistry 20 15%
Neuroscience 13 10%
Psychology 9 7%
Biochemistry, Genetics and Molecular Biology 8 6%
Other 29 22%
Unknown 30 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2013.
All research outputs
of 12,568,230 outputs
Outputs from Translational Neurodegeneration
of 130 outputs
Outputs of similar age
of 143,077 outputs
Outputs of similar age from Translational Neurodegeneration
of 1 outputs
Altmetric has tracked 12,568,230 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 130 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,077 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them